Risperidone ER is under clinical development by Lyndra Therapeutics and currently in Phase I for Bipolar I Disorder. According to GlobalData, Phase I drugs for Bipolar I Disorder have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Risperidone ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Risperidone ER overview
Risperidone ER is under development for the treatment of schizophrenia, schizoaffective disorder and bipolar 1 disorder. It is administered through oral route. The drug candidate is formulated as extended-release capsule. It acts by targeting D2 receptor and 5-HT2 receptor. The drug candidate is developed based on ultra long-acting oral drug delivery technology. In this technology, the dosage form is encapsulated in a gelatin capsule and it has star-shaped configuration.
Lyndra Therapeutics overview
Lyndra Therapeutics (Lyndra) is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. The company’s proprietary LYNX drug delivery platform is designed to deliver medicine in an oral form for a week or longer. Its lead product candidate, oral weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. Its other product candidates include LYN-006, LYN-045, LYN-047, LYN-014, LYN-013, LYN-064 and LYN-163. Lyndra developing therapies in psychiatry, cardiometabolic diseases and other conditions. The company operates its offices and research and development facilities in Watertown and Lexington, Massachusetts, the US. Lyndra is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Risperidone ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
